Advertisement

Topics

X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity

08:30 EDT 16 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Clinical data demonstrate single agent X4P-001-IO increases immune cell infiltration and activation in the tumor microenvironment (TME) Supportive preclinical data show robust anti-tumor activity of CXCR4 inhibition in ...

Other Sources for this Article

The Yates Network
Kathryn Morris, 914-204-6412
kathryn@theyatesnetwork.com

NEXT ARTICLE

More From BioPortfolio on "X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...